{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-031041","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.417954+00:00","generated_at":"2026-05-17T12:48:56.956947+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin Q2 net loss $7.6M ($0.12/sh); secures $10M credit line from chairman","bullets":["Net loss applicable to common stockholders of $7.6M ($0.12 per share) vs $12.4M ($0.20) in Q2 2024.","R&D expenses fell to $3.3M from $9.8M due to NAVIGATE trial completion in Q1 2025.","Cash and equivalents $13.8M at June 30; $10M line of credit from chairman closed July 8.","Company expects sufficient funding to operate through June 30, 2026.","NAVIGATE data at EASL showed belapectin reduced liver stiffness progression over 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-031041","json":"https://secwatch.observer/filing/0001140361-25-031041.json","markdown":"https://secwatch.observer/filing/0001140361-25-031041.md","text":"https://secwatch.observer/filing/0001140361-25-031041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/0001140361-25-031041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/ef20053791_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:48:56.956947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}